Age Related Macular Degeneration - The Recent Advances in Basic Research and Clinical Care 2012
DOI: 10.5772/33520
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of Neovascular Age Related Macular Degeneration

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 62 publications
(47 reference statements)
0
1
0
Order By: Relevance
“…Brolucizumab has a higher rate of SII (>4%) than other anti-VEGF agents [ 50 , 51 ]. It is unclear why this medication results in higher rates of SII, especially given it does not contain an Fc fragment which is considered the possible immunogenic factor in aflibercept and bevacizumab.…”
Section: Sterile Intraocular Inflammationmentioning
confidence: 99%
“…Brolucizumab has a higher rate of SII (>4%) than other anti-VEGF agents [ 50 , 51 ]. It is unclear why this medication results in higher rates of SII, especially given it does not contain an Fc fragment which is considered the possible immunogenic factor in aflibercept and bevacizumab.…”
Section: Sterile Intraocular Inflammationmentioning
confidence: 99%